(Reuters) ¨C U.S. lawmakers have asked Gilead

 Sciences Inc to explain the $84,000 price tag of its

 new hepatitis C drug Sovaldi, which is encountering resistance

 from health insurers and state Medicaid programs.

Separately on Friday, Gilead confirmed that it had agreed to

 supply the new drug in Egypt ¨C which has the world¡¯s highest

 prevalence of the virus due to use of contaminated needles in

 the 1970s ¨C at around $900 for a 12-week course of therapy, or

 about 1 percent of the U.S. price.

A letter to Gilead from Democrats in the House Energy &

 Commerce Committee, including ranking member Henry Waxman, asks

 for information on the company¡¯s pricing methodology and its

 impact on public health.